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Summary. Background: During the study of a family with
hereditary factor (F)V deﬁciency (FV Amersfoort,
1102 A > T in exon 7) we identiﬁed an individual with
5% FV heavy chain antigen (FVHC) and 50% FV light
chain antigen (FVLC). Further testing revealed that apart
from the FV Amersfoort allele a second variant FV allele
was segregating in this family, which encodes for a FV
molecule with a reduced aﬃnity for mAb V-23 used in the
FV heavy chain ELISA (ELISAHC). Objective: Identiﬁca-
tion and characterization of the molecular basis responsible for
the reduced aﬃnity of the variant FV for mAb V-23.
Methods: Family members of the proband were screened for
mutations in the exons coding for the heavy chain of FV, after
which the recombinant variant FV could be generated and
characterized. Next, the cases and controls of the Leiden
Thrombophilia Study (LETS)were genotyped for carriership of
the variant FV.Results: In the variant FV allele a polymorph-
ism in exon 3 (409G > C) was identiﬁed, which predicts the
replacement of aspartic acid 79 by histidin (D79H). Introduc-
tion of this mutation in recombinant FV conﬁrmed that it
reduces the aﬃnity for binding to mAb V-23. The substitution
has no eﬀect on FV(a) stability and Xa-cofactor activity. In
Caucasians the frequency of the FV-79H allele is 5%.
Analysis of the LETS revealed that the FV-79H allele is not
associatedwithFV levels (FVLC), activated proteinC sensitivity
(using an activated partial thromboplastin time-based test)
or risk of venous thrombosis (OR 1.07, CI 95: 0.7–1.7).
Conclusion: The D79H substitution in FV should be consid-
ered as a neutral polymorphism. The monoclonal antibody V-
23, which has a strongly reduced aﬃnity for FV-79H, is not
suitable for application in diagnostic tests.
Keywords: APC-resistance, factor V, polymorphism, venous
thrombosis.
Introduction
Human coagulation factor (F)V is a large plasma glycoprotein
that plays an important role in blood coagulation. In plasma,
FV circulates as a single-chain procofactor and is activated by
thrombin via limited proteolysis [1–3]. Activated FV (FVa)
consists of two polypeptide chains (designated as heavy and
light chain), which are non-covalently linked via a Ca2+ ion [4].
FVa serves as the non-enzymatic cofactor of the serine protease
Xa, which is responsible for the proteolytic activation of
prothrombin in the prothrombinase complex, consisting of
FVa, FXa, and negatively charged phospholipids. Down-
regulation of FVa is mediated by activated protein C (APC)
through proteolytic cleavage of the heavy chain of FVa at
Arg306, Arg506 and Arg679 [5]. Procofactor FV contains also
APC-cofactor activity in the inactivation of FVIIIa [6,7].
FV plays an important role both in the up and down-
regulation of thrombin generation (see also reviews [8] and [9]).
This dual role of FV is reﬂected in the disorders associated with
molecular defects in FV, which can be either hemorrhagic or
thrombotic. A mild to severe bleeding tendency has been
reported in patients with nonsense or missense mutations in the
FV gene (F5) which prevent FV synthesis or result in
dysfunctional FV (a large selection of FV mutations is
summarized in references [8] and [10]). On the other hand the
common R506Q mutation (FV Leiden), which impairs degra-
dation of FVa by APC, is associated with an increased risk of
venous thrombosis [11–13].
Measurement of FV antigen levels is an important tool in the
laboratory diagnosis of FV deﬁciency (parahemophilia), which
is a rare autosomal recessive bleeding disorder with an
estimated prevalence of 1–1000 000 [14]. Also, in the laboratory
screening of thrombophilia FV antigen measurements are
important, as compound heterozygosity for FV Leiden and a
FV null allele results in a pseudo-homozygous phenotype
(severe APC-resistance) [15–20].
Correspondence: Dr R. M. Bertina, Hemostasis and Thrombosis
Research Center, Department of Hematology, Leiden University
Medical Center, C2-R, PO Box9600, 2300RC, Leiden, the Netherlands.
Tel.: +31 71 5261894; fax: +31 71 5266755; e-mail: rmbertina@
lumc.nl
Received 16 November 2003, accepted 16 January 2004
Journal of Thrombosis and Haemostasis, 2: 910–917
 2004 International Society on Thrombosis and Haemostasis
Several immunologic assays for the measurement of FV
in plasma are available. In our laboratory we have developed
two enzyme-linked immunosorbent assays (ELISA) for
measuring FV antigen, one for the light chain and one
for the heavy chain. The light chain ELISA (ELISALC) has
ﬁrst been described by Guasch et al. [21] and uses two
murine monoclonal antibodies (mAbs), V6 and V9, the
epitopes of which have been mapped on the light chain of
FVa. The heavy chain ELISA (ELISAHC) uses two murine
mAbs (V-23 and V39) directed against the heavy chain of
FVa.
During the study of the family of an asymptomatic
heterozygous carrier of the FV Amersfoort allele (1102 A >
T in exon 7 [22]), we observed a striking discrepancy between
FV light chain and heavy chain antigen levels in some of the
familymembers. Further analysis showed that this abnormality
cosegregated with a 409G > C transversion in exon 3 of F5
predicting an amino acid substitution (D79H) in the heavy
chain of FV (ﬁrst reported by Cargill et al. [23]). So far, the
effect of the D79H substitution on the function of FV is not
clear. Recently, however, it has been reported that carriership
of FV-79H is associated with moderately decreased FV levels
and may serve as a trans-acting gene mutation in heterozygous
carriers of FV Leiden by lowering the sensitivity of plasma to
APC [24]. The latter observations prompted us to further
investigate the effects of the D79H substitution on FV
function, FV levels, APC-sensitivity ratios and risk of venous
thrombosis.
Materials and methods
Materials
Plasmid isolation kits were from Qiagen (Chatsworth, CA,
USA). DNA restriction fragments were puriﬁed from
agarose gel using the Cleanmix kit (Talent, Trieste, Italy).
Bovine Serum Albumin (BSA), benzamidine, phosphatidyl-
choline (PC), N-hydroxy-succinimidobiotin was from Sigma
(St. Louis, MO, USA). Dioleoylphospatidylcholine (DOPC)
and dioleoylphospatidylserine (DOPS) were obtained from
Avanti Polar Lipids (Alabaster, Al, USA). dNTP were
from Serva (Heidelberg, Germany). Chromogenic sub-
strate S-2238 was obtained from Chromogenix (Uppsala,
Sweden).
Proteins
Restriction enzymes were fromNew England Biolabs (Beverly,
MA, USA). Human FXa was fromHematologic Technologies
Inc. (Essex, VT, USA). Amplitaq DNA polymerase was from
Applied Biosystems (Foster City, CA,USA). Activated protein
C, prothrombin, thrombin and sheep anti-FV polyclonal
antibody were purchased from Enzyme Research Laboratories
(South Bend, IN, USA). NeutraliteTM Avidin-HRP conjugate
was from Southern Biotechnology Associated Inc. (Birming-
ham, AL, USA).
FV deficient family
We studied the family of an asymptomatic FV deﬁcient
individual who was heterozygous for an 1102-A > T substi-
tution in exon 7 (FV Amersfoort, see van Wijk et al. [22]).
FV antigen assays
FV light chain antigen was detected in an ELISA using two
different monoclonal antibodies (mAbs) directed against the
light chain of FV as described before [21,25]. In this ELISA,
mAb V-6 was used as a coating antibody and biotinylated
mAb V-9 as tagging antibody. FV heavy chain antigen was
detected in an ELISA recently developed in our laboratory.
This ELISA shows identical dose–response curves for plasma
and serum FV, indicating that it identiﬁes a fragment of the
heavy chain of FVa, which is not cleaved during activation
or inactivation of FV(a). Monoclonal antibody mAb V-23
was used as coating antibody and biotinylated mAb V-39 as
tagging antibody. For both light chain and heavy chain
ELISA, samples were diluted in 50 mM triethanolamine
(TEA), 100 mM NaCl, 10 mM EDTA and 0.1% Tween,
pH 7.5. Dilutions of pooled normal plasma (1 : 25–1 : 1600
dilution) were used to calibrate the assays. Results are
expressed in percentage, where 100% refers to the concen-
tration of FV in pooled normal plasma.
DNA amplification and sequence analysis
The exons coding for the heavy chain of FV were ampliﬁed
according to standard polymerase chain reaction (PCR)
procedures using 0.1–1 lg genomic DNA. Details about
primers and conditions are available on request
(rjdirven@lumc.nl). Sequence reactions were performed using
the CEQ2000TM Dye Terminator Cycle Sequencing Kit
(Beckman Coulter Inc., Fullerton, CA, USA) according to
the instructions of themanufacturer and subsequently analyzed
on a SEQTM8000 Genetic Analysis System (Beckman Coulter
Inc., Fullerton, CA, USA). Nucleotides of the cDNA were
numbered according to Jenny et al. [26].
Mutagenesis
Expression vector pMT2FV [27] was used as template to
introduce the D79H (409G > C) variation in the heavy chain
of FV. Mutations were introduced using the QuikchangeTM
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA,
USA). The forward mutagenic oligonucleotide used for
construction of rFV-79H was:
5¢-GTTCACTTTAAGAATAAGGCACATAAGCCCTT-
GAGC-3¢
The nucleotide responsible for the missense mutation is
presented in bold and underlined. In this oligo an additional
silentmutation (in bold) was introduced, which removes aDraI
restriction site, to serve as a marker. After mutagenesis, the
presence of the mutations was conﬁrmed by direct DNA
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sequencing. Finally, the mutated fragment was inserted into a
non-mutagenized pMT2FV by exchange of the appropriate
restriction enzyme fragments. Details about this procedure are
available on request.
Transient expression of recombinant FV
Recombinant FV was transiently expressed in COS-1 cells
(75 cm2 culture ﬂasks) using Fugene 6 Transfection Reagent
(Roche Molecular Biochemicals, Hague Road, IN, USA).
Twenty-four hours after transfection cells were washed with
phosphate-buffered saline (PBS) and incubatedwith serum-free
medium (Optimem Glutamax, Life Technologies Ltd, Paisley,
UK).Conditionedmediumwasharvestedafter72 h,centrifuged
for 20 min at 1000 r.p.m. (200 g) (4 C) and frozen at)20C.
FV activity assay
Total FV activity was measured in a two-step procedure as
described before [28,29]. Brieﬂy, FV was completely activated
by 5 nM thrombin in HBS-Ca (25 mM Hepes, 175 mM NaCl,
3 mM CaCl2, 5 mg mL
)1 BSA, pH 7.5) during a 20-min
incubation at 37 C in a ﬁnal volume of 150 lL. Subsequently,
10 lL was transferred to a 96 wells plate, 100 lL of
prothrombinase mix (HBS-Ca containing FXa and DOPS/
PC 10 : 90 molar ratio) was added and after 5 min the
prothrombinase reaction was started by addition of 25 lL
prothrombin (1.47 lM) in HBS-Ca. Final concentrations were:
FXa (125 pM), prothrombin (280 nM) and DOPS/PC (50 lM).
After a 4-min incubation at room temperature the reaction was
stopped with 50 lL TN-EDTA (50 mM TRIS, 175 mM NaCl,
50 mM EDTA, 5 mg mL)1 BSA, pH 7.9). After the addition
of 25 lL chromogenic substrate S-2238 (2.35 mM), the amount
of thrombin formed was measured kinetically on a Spectra III
Thermo microtiter plate reader from Tecan (Salzburg, Aus-
tria). The assay was calibrated using dilutions of pooled normal
plasma (PNP) corresponding with 0–3 pM of FV.
FV(a) stability
FVa stability was assessed by following the spontaneous loss
of Xa-cofactor activity as a function of time in the presence
and absence of phospholipids as described before [30].
Spontaneous inactivation rates were obtained by ﬁtting the
curves in a single-exponential model using non-linear least-
squares analysis.
Synthetic peptides overlapping region of amino acid 79
Two synthetic peptides were constructed homologous to the
amino acid sequence of human FV with either an aspartic acid
or histidine at position 79:
PEP79D: 71-KVHFKNKADKPLSIH-85 (D at residue 79)
PEP79H: 71-KVHFKNKAHKPLSIH-85 (H at residue 79)
The afﬁnity of these peptides for mAb V-23 was assessed
from experiments in which plasma FV was used as competitor.
In brief, a 96-wells plate was coated with mAb V-23, after
which the wells were incubated with pooled normal plasma
(1/300 diluted in a buffer containing 50 mM TEA, 100 mM
NaCl, 10 mM EDTA and 0.1% Tween, pH 7.5), mixed 1 : 1
with increasing concentrations of peptides in 50 mM TEA,
100 mMNaCl, pH 7.5 (ﬁnal concentration 1 mM). After wash-
ingwithELISAbuffer, theplatewas incubatedwithbiotinylated
sheep antihuman FV polyclonal antibody (1 : 500 dilution),
which was detected with Neutralite Avidin-HRP. In the ﬁnal
step, the plate was colored with 3,3¢,5,5¢-tetramethylbenzidine.
Study population
Patients and control subjects included in the present study were
from a large population-based case-control study on risk
factors for a ﬁrst venous thrombosis, the Leiden Thrombo-
philia Study (LETS), which has been described in detail before
[31,32].
Detection of 409G > C transversion in genomic DNA
Carriership of the 409G > C transversion in exon 3 of the F5
(corresponding to the D79H mutation) was detected by PCR
followed by restriction enzyme digestion. The PCR was
performed using 0.1–1 lg genomic DNA, 200 ng primers,
200 lM dNTP and 1 University of Taq DNA polymerase in
PCR buffer containing 67 mM TRIS-HCl (pH 8.8), 6.7 mM
MgCl2, 6.7 lM EDTA, 16.6 mM (NH4)2SO4, 0.1 mg mL
)1
BSA, 10% DMSO and 10 mM,-mercapto-ethanol. A 208-bp
fragment was ampliﬁed with the following primers:
Primer A: (5¢-GGAGGAATGGTAGCAATCACTCTT-
GG-3¢)
Primer B (5¢-TCCTTGAGGATGGATGCTCAGATGCT-
TAT-3¢)
InprimerBamismatchsequence (underlined)was introduced
to generate a BsaBI restriction site after ampliﬁcation of the
FV-79D allele. Digestion of this fragment by BsaBI resulted in
cleavage products of 25 bp and 183 bp, whereas the ampliﬁed
fragment of the FV-79H allele was not digested by BsaBI.
APC-resistance test
The activated partial thromboplastin time (APTT)-basedAPC-
sensitivity ratio (APC-SR) was measured as described by
Koster et al. [31]. APC-sensitivity ratios were normalized by
dividing them by the APC-SR of pooled normal plasma.
Statistical analysis
Odds ratios (ORs) and 95 per cent conﬁdence intervals (95%
CI) were calculated in the standard unmatched fashion. The
OR estimates the risk of venous thrombosis in the presence of a
risk factor (e.g. carriership of the FV-79H allele) relative to the
absence of the particular risk factor, the reference category. An
OR of 1 indicates no effect on risk, while an OR above 1
indicates an increase in risk.
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Results
FV activity and antigen in FV deficient family
FV Amersfoort is characterized by the 1102 A > T substitu-
tion in exon 7 of F5, resulting in a premature stop at codon 310
[22]. To investigate whether the truncated FV protein (amino
acids 1–310) is expressed in plasma, we measured FV heavy
chain antigen (FVHC) and FV light chain antigen (FVLC) in
plasma of an asymptomatic heterozygous carrier of FV
Amersfoort and his ﬁrst-degree relatives. The results are
summarized in Table 1. In none of the FV Amersfoort carriers
(father, child 1 and child 2) an excess of FVHC was observed,
because in none of the plasma samples the FVHC/FVLC ratio
exceeded 1. Remarkably, in some individuals the FVHC level
was much lower than the FVLC level, resulting in strongly
reduced FVHC/FVLC ratios. The mother, child 1, 2 and 4 all
seemed to be heterozygous for a variant FV molecule, which is
poorly recognized by one or both mAbs used in the ELISAHC.
To test this, three additional FV ELISAs were designed using
either mAb V-23, V-39 or V-6 as catching antibody and a
polyclonal anti FV conjugate as tagging antibody. Subse-
quently, plasma of child 1 (FVHC/FVLC ratio 0.07) was
analyzed with these ELISAs. The FV antigen levels were 0%,
41% and 61% as measured with ELISAV-23, ELISAV-39 and
ELISAV-6, respectively, which indicates that mAb V-23 poorly
recognizes FV in this individual.
Identification of an immunologic polymorphism in the heavy
chain of FV
The absence of an epitope for mAb V-23 in the FV of
some members of this FV deﬁcient family most likely is the
result of an amino acid substitution in the heavy chain of
FV. Therefore, we sequenced the exons coding for the heavy
chain of FV of the father and the mother. In total ﬁve
nucleotide changes with respect to the sequence of Jenny
et al. were identiﬁed (summarized in Table 2) including the
FV Amersfoort mutation in exon 7. From the data in
Table 1 and Table 2 haplotypes were constructed (Fig. 1).
Carriership of the haplotype 327 A, 409C, 495 A, 642T,
1102 A cosegregated with reduced FVHC/FVLC ratios.
Within this haplotype only the 409G > C polymorphism
in exon 3 predicts an amino acid substitution (D79H). This
made the D79H substitution a good candidate for the
mutation that causes the reduced afﬁnity for mAb V-23. It
should be noted that the 409G > C transversion is also
present in the FV Amersfoort allele (1102T), which is not
expressed in plasma. Therefore, some members of this
family are heterozygous for the D79H substitution, whereas
they have a normal FVHC/FVLC ratio (i.e. child 2).
Analysis of the epitope of mAb V-23
To conﬁrm that the molecular basis of the reduced afﬁnity of
FV for mAb V-23 resides in the D79H mutation, we
introduced this mutation in an expression vector containing
the cDNA of human FV (pMT2-FV). After transfection of
COS-1 cells, conditioned medium containing recombinant
FV was collected and analyzed (Table 3). The expression
levels of both rFV-79D and rFV-79H were similar as
measured by functional FV assay and ELISALC (7% of
normal plasma level), which indicates that rFV-79H has a
normal speciﬁc activity (FVa/FVLC). However, using the
ELISAHC very low FV levels were detected in medium
containing rFV-79H, while the FVHC in the medium of
rFV79D was similar to the FVLC. This conﬁrmed that the
ELISAHC was affected by the D79H substitution, which
most likely disrupts the epitope of mAb V-23 (see also ﬁrst
section of Results).
We tried to obtain more information about the epitope of
mAb V-23 using synthetic peptides. Two peptides (PEP-79D
and PEP-79H) homologous to the region surrounding amino
acid 79 were synthesized and tested for their ability to compete
with plasma FV for binding to mAb V-23. However, peptide
concentrations up to 1 mg mL)1 did not affect the binding of
plasma FV to mAb V-23 (data not shown).
The region surrounding residue 79 was also analyzed in a
3-dimensional model for the heavy chain of FVa [33]. This
model revealed that this region is surface exposed, indicating
that it might contain an epitope for an antibody. Replacement
of 79D by 79H did not result in conformational changes in the
experimental FVamodel (data not shown), which suggests that
Table 1 FV activity and antigen levels in members of FV deﬁcient family
Family FV activity2 (%) FVLC (%) FVHC (%) FVHC/FVLC
Father 1 34 51 41 0.80
Mother 125 136 89 0.65
Child 11 62 69 5 0.07
Child 21 60 64 65 1.02
Child 3 109 142 69 0.49
Child 4 93 136 57 0.42
1Heterozygous carrier of the FV Amersfoort allele. 2FV activity was
measuredusingaone stage clotting assay (data fromvanWijk et al. [22]).
Table 2 Polymorphisms in exons coding for FV heavy chain in members
of FV deﬁcient family
Exon
(Amino
acid
change)
Nucleotide
change Father Mother
Child
1
Child
2
Child
3
Child
4
Exon 2 327G > A
(Q51Q)
GA AA AA AA GA GA
Exon 3 409G > C
(D79H)
GC GC CC GC GC GC
Exon 4 495G > A
(A107A)
GA GA AA GA GA GA
Exon 4 642G > T
(S156S)
GT GT TT GT GT GT
Exon 7 1102 A > T1
(K310Term)
AT AA AT AT AA AA
1Mutation resulting in premature stop (FV Amersfoort) [22].
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the D79H substitution affects electrostatic interactions between
the epitope and mAb V-23.
Finally, conservation of region surrounding amino acid 79
was analyzed between different species. In Table 4 the amino
acid sequences surrounding residue 79 (residues 71–85) of 7
different species are shown. Homology ranges from 60% for
the zebraﬁsh to 93% for some mammals. The aspartic acid at
position 79 was conserved between several species, but not in
cow and pipid frog.
Further characterization of the D79H substitution
Recently, it has been reported that carriership of the FV-79H
allele is associated with moderately reduced FV activity in
plasma [24], as measured in a one stage clotting assay. Also,
indications have been obtained that carriership of the FV-79H
allele may lower the APC sensitivity in subjects carrying the FV
Leiden allele [24]. Therefore, it may act as a trans-acting gene in
carriers of FV Leiden in a similar way as has been demonstra-
ted for the FV-R2 allele [34–37]. To further investigate this, we
genotyped the cases and controls from a large population-
based case-control study on risk factors for venous thrombosis
(LETS) and determined the effect on FV levels, n-APC-SR and
risk of thrombosis.
To investigate the effect of the D79H substitution on
plasma FV levels, we used the data from the 433 healthy
controls from the LETS. Carriers of the FV-R2 allele were
excluded from this analysis (no compound heterozygous
carriers of the FV-79H allele and FV-R2 were found in this
group). Table 5 shows that the mean FVLC level in carriers
of the FV-79H allele (138 U dL)1) is similar to that in non-
carriers (133 U dL)1).
Fig. 1. Pedigree of FV deﬁcient family. In this pedigree FV deﬁciency (FV Amersfoort) and reduced FV(HC)/FV(LC) antigen ratios (Table 1) are
indicated together with the genotypes for the polymorphisms found in the exons coding for the heavy chain (Table 2). The proband of this family is child 1.
Table 3 Speciﬁc activity and FVHC/FVLC ratio of recombinant FV-79D
and FV-79H. FV activity and FV antigen (FVHC and FVLC) were meas-
ured in conditioned medium containing either rFV-79D or rFV-79H
rFV FVa/FVLC
1 FVHC/FVLC
rFV-79D 0.94 0.83
rFV-79H 1.04 0.06
1FV activity was measured as described in Materials and methods.
Table 4 Alignment of amino acid sequence surrounding residue 79 in the
heavy chain of FV. Conservation of the region surrounding position 79
(residue 71–85) in the heavy chain of FV was assessed by comparing the
human amino acid sequence with the amino acid sequence of 6 diﬀerent
species. Position 79 is bold and underlined
Species FV amino acid sequence Homology
Homo sapiens KVHFKNKADKPLSIH –
Bos taurus KVHFKNKAHKPLSIH 93%
Mus musculus KVHFRNKADKPLSIH 93%
Sus scrofa KVHFRNKADKPLSIH 93%
Gallus gallus VVHFKNMADKPISIH 87%
Xenopus tropicalis QVHFKNMANKPLTIH 80%
Danio rerio IVTFRNMADHPCSLH 60%
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Theoretically, the reduced procoagulant FV activity reported
by Bossone et al. [24] for carriers of FV-79Hmay be caused by
increased instability of the activity of FV-79H. To assess this
possibility, the loss of (activated) rFV activity was followed as a
function of time. The ﬁrst-order rate constant for spontaneous
inactivation (ks) of rFV-79D was similar to that for rFV-79H,
being around 3.0 · 10)6 s)1 (Table 6). Also the ks for activated
rFV-79D was similar to that for activated rFV-79H, being
around 3.0 · 10)5 s)1. The presence of phospholipids did not
inﬂuence the stability of the activated rFV molecules.
Next, we investigated the effect of the D79H substitution on
theAPTT-based normalized-APC sensitivity ratio [31]. For this
analysis carriers of FV Leiden were excluded. The n-APC-SRs
in the absence of the FV Leiden mutation are summarized in
Table 5 anddemonstrate that carriershipof theFV-79Hallele is
not associated with a lower n-APC-SR. Exclusion of FV-R2
carriersdidnotalter this result (datanot shown). In this analysis,
it was not possible to investigate whether carriership of
FV-Leiden in trans with the FV-79H allele is associated with a
further decrease of the n-APC-SR, because none of the healthy
controls were compound heterzozygous for FV-Leiden and
FV-79H. Therefore, we screened all patients in the LETS for
compound heterozygosity for FV-Leiden and FV-79H. In total
8 patients were found compound heterozygous for FV-Leiden
and FV-79Hwith a mean n-APC-SR of 0.57 (range 0.53–0.64).
Finally, we analyzed the association of the D79H substitu-
tion with risk of thrombosis. For this analysis all cases and
controls of the LETS were genotyped for this polymorphism.
The allele frequency of the FV-79H allele was 5.0% in patients
and 4.7% in controls (Table 7), which is in agreement with
previously reported allele frequencies (5–15%) in different
healthy Caucasian populations [23,24]. The odds ratio (OR),
calculated as a measure of the relative risk of venous
thrombosis, for subjects carrying the FV-79H allele (both
heterozygous and homozygous) was 1.07 (CI 95: 0.7–1.7)
compared to homozygous FV-79D carriers. Exclusion of all
FV Leiden carriers did not alter this OR.
Discussion
In this study, we have analyzed a variant FV that was not
recognized by a monoclonal antibody (mAb V-23) directed
against the heavy chain of FV. Haplotype analysis of the
variant FV allele suggested that an amino acid substitution at
residue 79 (D79H) was responsible for the absence of the
epitope for mAb V-23. This was conﬁrmed by introducing this
substitution in recombinant FV (rFV-79H). Functional tests
with rFV-79H showed that this substitution did not affect the
Xa-cofactor function or the stability of FV(a). Furthermore,
carriership of the FV-79H allele (allele frequency 5%) is not
associated with FV levels (FVLC), APC sensitivity (using an
APTT-based test) or risk of venous thrombosis (OR 1.07, CI
95: 0.7–1.7). Together, these results indicate that the frequent
D79H polymorphism in FV is neutral.
Initially, we were interested in the question whether
truncated FVmolecules were expressed in plasma from carriers
of the FV Amersfoort allele, which refers to a 1102-A > T
mutation in exon 7 of F5 resulting in a premature stop in codon
310 [22]. For this purpose plasma samples of the relatives of a
heterozygous carrier of FV Amersfoort were screened with
ELISAs for FV heavy chain (FVHC) and FV light chain
(FVLC). Recent data indicate that both antibodies used in the
ELISAHC recognize an epitope at the amino-terminal end (1–
306) of FV (data not shown). Because no FVHC/FVLC ratios
higher than 1 were observed (Table 1) it seems unlikely that
substantial amounts of FVAmersfoort are expressed, although
it can not excluded that the afﬁnity of the truncated FV
molecule for mAb V-23 or V-39 has been affected. This
possibility could not be tested, because we have not generated
recombinant FV Amersfoort. Instead, we have tested another
truncated rFV molecule, labeled M-fragment, consisting of the
ﬁrst 909 amino acids of FV, which has been constructed before
[29]. This showed that the afﬁnity of the M-fragment for Mab
V-23 and V-39 was not affected (data not shown). Taken
together, it seems most likely that mRNA transcribed from the
Table 5 FV antigen levels (U dL)1) and APC sensitivity ratios according
to carriership of FV-79H. Carriership of FV-79H allele, FV light chain
(FVLC) levels and n-APC-SR were determined in control subjects of the
LETS
D79H
FVLC1 n-APC-SR2
n
Mean (95% CI)
(U dL)1) n Mean (95% CI)
D/D 390 133 (130–139) 374 1.02 (1.01–1.03)
D/H 42 138 (129–147) 42 1.05 (1.02–1.08)
H/H 1 115 1 0.98
1FV-R2 carriers (n ¼ 38) were excluded. 2FV Leiden carriers and
individuals using oral anticoagulants were excluded (n ¼ 54).
Table 6 Stability of recombinant FV-79D and FV-79H in the absence or
presence of phospholipids. Spontaneous inactivation rates (ks) were ob-
tained by ﬁtting time courses (30 h) of rFV(a) inactivation with a single
exponential. Incubation conditions are described inMethods (1 nM FVa
in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl2, 5 mg mL
)1
BSA ± 24.5 lM phospholipids (10 : 90 DOPS:DOPC) at 37 C)
FV +PL – PL
Spontaneous inactivation rates (s)1)
rFV-79D N.D. 3.0 · 10)6
rFV-79H N.D. 2.6 · 10)6
Activated
rFV-79D 5.1 · 10)5 2.6 · 10)5
Activated
rFV-79H 6.2 · 10)5 3.6 · 10)5
Table 7 Frequencies of D79H polymorphism in LETS
D79H Patients Controls
D/D 426 428
D/H 45 42
H/H 1 1
Odds ratio of FV-79H carriers: 1.07 (CI 95: 0.7–1.7).
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FV Amersfoort allele is degraded in the nonsense-mediated
mRNA decay pathway [38].
Unexpectedly, we observed strongly reduced FVHC/FVLC
ratios in some family members (see Table 1). This observation
suggested that in this family a variant FV was segregating,
which was poorly recognized by one of the mAbs (V-23 or
V-39) used in our ELISAHC. Further testing revealed that mAb
V-23 poorly recognized this variant FV and that the strongly
reduced FVHC/FVLC ratios cosegregated with a FV haplotype
containing one single missense mutation in the heavy chain
(D79H). This made this mutation a strong candidate to affect
the epitope for mAb V-23 (Fig. 1). Introduction of the D79H
mutation in recombinant FV conﬁrmed that it strongly reduced
the afﬁnity for mAb V-23 (FVHC/FVLC antigen ratio for rFV-
79H is0.06 compared to 0.83 for rFV-79D, Table 3). Further
tests revealed that mAb V-23 did not bind synthetic peptides
homologous to the region around residue 79 (71–85). This
cannot easily be explained by the absence of post-translational
modiﬁcations on these peptides, because in the region from 71
to 85 no modiﬁcations are known. This suggests that the
epitope for mAb V-23 is not linear, which is in agreement with
the observation that mAb V-23 did not detect FV in Western
blots under reducing conditions (data not shown). Further-
more, replacement of 79D into 79H in the experimental model
of FVa [33] did not result in conformational changes in the
heavy chain of FVa, which suggests that the D79H mutation
rather has an effect on the electrostatic interactions between the
epitope and mAb V-23.
Little is known about the effect of the D79H substitution on
the function of FV. So far, this polymorphism has only been
reported twice. The ﬁrst time was in 1999 in a study by Cargill
et al. [23]. They included this polymorphism in an extensive
catalog of single-nucleotide polymorphisms (SNPs) in the
coding regions of human genes, which could be used in
association studies. This report, however, gives no information
on the functionality of this polymorphism. More recently, it
has been reported that carriership of FV-79H is associated with
slightly reduced procoagulant FV activity levels and possibly
with a lower sensitivity to APC in heterozygous carriers of the
FV Leiden allele [24]. This suggested that the D79H substitu-
tion, in analogy to the FV-R2 mutation, increases the APC-
resistent phenotype of plasma fromheterozygous carriers of the
FV Leiden mutation via reduced FV expression of the FV-79H
allele [34,39].
We did not observe an association between carriership of the
FV-79H allele and lower FVLC levels in 433 healthy individuals
from the LETS (Table 5). This suggests that this allele is not
associated with reduced FV antigen levels, which seems to be
different from the results reported by Bossone et al. [24]. This
maybe explainedby the relatively small size of the group studied
by Bossone (n ¼ 150 compared to 433 in our study). It also is
possible thatFV-79Hhas a slightly reduced speciﬁcprocagulant
activity. However, we found no indications that the D79H
substitutionhasan effect on theXa-cofactor activity ofFVa: the
speciﬁc activity (FVa/FVLC) of rFV-79H was similar to that of
rFV-79D (Table 3). This is in agreement with the results from
Zeibdawi et al. [40], who studied the effect of the D79A
substitution on the cofactor function of FVa. Also, the D79H
substitution did not affect the stability of the (activated) FV
molecule (see Table 6), like the amino acid substitutionsA221V
andD111A,whichhavebeen reported toweaken the interaction
between the heavy and light chain of activated FV [40,41].
Carriership of the FV-79H allele is not associated with a
lower n-APC-SR after exclusion of FV Leiden carriers
(Table 5), which is in line with the ﬁndings from Bossone et al.
[24]. We did not ﬁnd that heterozygous carriers of FV Leiden,
who carry the FV-79H allele on the other chromosome have a
more APC-resistant phenotype than subjects (n ¼ 8) carrying
the alleles for FV Leiden and FV-79D (mean n-APC-
SR ¼ 0.57). This ratio is identical to the ratio of 0.57 (range
0.5–0.67) previously reported for heterozygous carriers of FV
Leiden [11,37]. Finally, carriership of the FV-79H has no effect
on the risk of venous thrombosis (Table 7), which is reﬂected in
an odds ratio of 1.07 (CI 95: 0.7–1.7).
Taken together, our data suggest that the D79H substitution
has no effect on FV(a) function or thrombosis risk. This is in
agreement with the fact that so far no functional domains have
been identiﬁed in the region surrounding residue 79 in FV (see
also the review by Mann and Kalafatis [8]). Also the fact that
the aspartic acid at position 79 is not fully conserved between
the species aligned in Table 4, suggests that residue 79 is not
critical for the function of FV.
We conclude that the D79H substitution should be consid-
ered as a neutral polymorphism with an allele frequency of
5% in the Caucasian population. FV-79H is poorly recog-
nized by mAb V-23. Therefore, it is recommended not to use
mAb V-23 in diagnostic tests, because it would result in falsely
reduced FV levels in 10% of the population.
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